Gilead Sciences, Inc. (NASDAQ:GILD) Stake Cut by Bard Financial Services Inc.

Bard Financial Services Inc. cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 30,095 shares of the biopharmaceutical company’s stock after selling 2,675 shares during the period. Bard Financial Services Inc.’s holdings in Gilead Sciences were worth $2,523,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Bellevue Group AG lifted its stake in Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after buying an additional 7,093 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after buying an additional 48,910 shares during the last quarter. Legal & General Group Plc lifted its stake in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after buying an additional 93,068 shares during the last quarter. IRON Financial LLC bought a new stake in Gilead Sciences in the third quarter valued at $830,000. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Gilead Sciences by 13.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after buying an additional 33,162 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 0.2 %

NASDAQ:GILD opened at $92.12 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The firm has a market capitalization of $114.81 billion, a price-to-earnings ratio of 1,026.00, a price-to-earnings-growth ratio of 2.86 and a beta of 0.18. The stock has a fifty day simple moving average of $89.33 and a 200 day simple moving average of $78.89.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the company posted $2.29 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Sell-side analysts forecast that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.34%. Gilead Sciences’s payout ratio is presently 3,422.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Barclays raised their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Truist Financial raised their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $74.00 to $96.00 in a report on Monday, October 21st. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.43.

Insider Activity

In related news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 476,591 shares of company stock worth $43,747,615 in the last three months. 0.29% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.